Eli Lilly and Company (NYSE:LLY) Shares Acquired by Cozad Asset Management Inc.

Cozad Asset Management Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 5.7% during the fourth quarter, Holdings Channel reports. The fund owned 19,103 shares of the company’s stock after purchasing an additional 1,037 shares during the quarter. Eli Lilly and Company comprises approximately 1.4% of Cozad Asset Management Inc.’s investment portfolio, making the stock its 13th largest position. Cozad Asset Management Inc.’s holdings in Eli Lilly and Company were worth $14,747,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Horizon Kinetics Asset Management LLC grew its position in Eli Lilly and Company by 3.4% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 4,257 shares of the company’s stock valued at $3,286,000 after buying an additional 141 shares in the last quarter. Kimelman & Baird LLC grew its position in Eli Lilly and Company by 21.8% in the 4th quarter. Kimelman & Baird LLC now owns 44,562 shares of the company’s stock valued at $34,402,000 after buying an additional 7,972 shares in the last quarter. Cassady Schiller Wealth Management LLC grew its position in Eli Lilly and Company by 10.1% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 458 shares of the company’s stock valued at $354,000 after buying an additional 42 shares in the last quarter. TCTC Holdings LLC grew its position in Eli Lilly and Company by 2.3% in the 4th quarter. TCTC Holdings LLC now owns 2,727 shares of the company’s stock valued at $2,105,000 after buying an additional 62 shares in the last quarter. Finally, Pitti Group Wealth Management LLC grew its position in Eli Lilly and Company by 3.0% in the 4th quarter. Pitti Group Wealth Management LLC now owns 1,708 shares of the company’s stock valued at $1,319,000 after buying an additional 49 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LLY shares. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Citigroup reduced their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Finally, Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Price Performance

Shares of LLY opened at $813.55 on Monday. The firm has a market cap of $771.38 billion, a PE ratio of 69.47, a PEG ratio of 1.40 and a beta of 0.34. The firm’s 50 day moving average price is $830.81 and its 200 day moving average price is $842.50. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has approved a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.